Vertex Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2023 / 03:30PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst

Well, thanks, everybody, for joining us. I'm Terence Flynn from the U.S. biopharma analyst here at Morgan Stanley and we're very pleased to be hosting Vertex for this session. Today from the company, we have Reshma Kewalramani, who's President and CEO; and Charlie Wagner, who is CFO. Thank you both so much for being here. I appreciate the time today.

Before we get started, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Questions and Answers:

Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst

With out of the way, Reshma and I again, we had the opportunity to speak last night and again got a kind of a great overview of the company. And so I guess the question I wanted to start with was more one on strategy. Obviously, part of
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot